PSMA, alternatively referred to as glutamate carboxy-peptidase II (GCPII), is a type II transmembrane zinc metalloenzyme that is highly expressed in the majority of prostate cancers and the neo-vasculature of many solid tumors [30]. Here, FOLH1 is linked to prostate cancer.